Announcements Trials
Browse Landscape

Phase

Phase NA 27Phase 2 6Phase 3 2Phase 1 2Phase 4 1Phase 2/3 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 372Neoplasms 325Neoplasm Metastasis 288Leukemia, Myeloid, Acute 280Breast Neoplasms 272Colorectal Neoplasms 239Melanoma 193Ovarian Neoplasms 190Recurrence 184Multiple Myeloma 178Prostatic Neoplasms 158Lung Neoplasms 158Pancreatic Neoplasms 151Squamous Cell Carcinoma of Head and Neck 150Lymphoma, Non-Hodgkin 147Glioblastoma 146Triple Negative Breast Neoplasms 119Myelodysplastic Syndromes 115Carcinoma, Renal Cell 111Stomach Neoplasms 110Glioma 109Brain Neoplasms 105Advanced Solid Tumors 105Precursor Cell Lymphoblastic Leukemia-Lymphoma 104Lymphoma, Large B-Cell, Diffuse 102Lymphoma 102Lymphoma, B-Cell 97Carcinoma, Hepatocellular 95Lymphoma, Follicular 92Endometrial Neoplasms 92

Interventions

pembrolizumab 1enfortumab vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Peripheral Nervous System Diseases × 1 year × Clear all
NCT06405542 2026-06-04

EX-CIPN

University Health Network, Toronto

Phase 1 Active not recruiting
40 enrolled

Peripheral Nervous System Diseases

NCT07484022 2026-06-03

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Generate Biomedicines

Phase 1 Recruiting
37 enrolled
Genitourinary

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡